AgeX Therapeutics, Inc. (AGE)
| Previous close | 0.7678 |
| Open | 0.8100 |
| Bid | 0.7559 x 2900 |
| Ask | 0.8100 x 1000 |
| Day's range | 0.7372 - 0.8061 |
| 52-week range | 0.7100 - 3.0600 |
| Volume | 225,670 |
| Avg. volume | 78,077 |
| Market cap | 29.085M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
ALAMEDA, Calif., November 23, 2021--AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 17, 2021 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stock
- Business Wire
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
ALAMEDA, Calif., November 12, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2021.
- Business Wire
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
ALAMEDA, Calif., August 13, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.
